Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
Written informed consent obtained from the subject prior to performing any study specific procedure.
A male or female between, and including, 18 and 50 years of age at the time of the first study visit.
Healthy subjects as established by medical history and clinical examination before entering into the study. Healthy subjects with no medical conditions that, in the opinion of the investigator, prevents the subject from participating in the study.
Subjects must weigh at least 110 pounds (50 kg), but not to present obesity (BMI < 32kg/m2).
Female subjects of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause.
has practiced adequate contraception for 30 days prior to vaccination, and
has a negative pregnancy test on the day of vaccination and
has agreed to continue adequate contraception during the entire treatment period and for 1 month, after completion of the vaccination series.

NCT03493919_inc_T2
Observation
comply with the requirements of the protocol
NCT03493919_inc_T3
Observation
Written informed consent
NCT03493919_inc_T4
Procedure
study specific procedure
NCT03493919_inc_T5
Temporal
prior to performing any study specific procedure
NCT03493919_inc_T6
Reference_point
performing any study specific procedure
NCT03493919_inc_T7
Person
male
NCT03493919_inc_T8
Person
female
NCT03493919_inc_T9
Value
18 and 50 years
NCT03493919_inc_T10
Person
age
NCT03493919_inc_T11
Temporal
at the time of the first study visit
NCT03493919_inc_T12
Reference_point
the first study visit
NCT03493919_inc_T13
Condition
Healthy
NCT03493919_inc_T14
Observation
medical history
NCT03493919_inc_T15
Procedure
clinical examination
NCT03493919_inc_T16
Temporal
before entering into the study
NCT03493919_inc_T17
Reference_point
entering into the study
NCT03493919_inc_T19
Measurement
weigh
NCT03493919_inc_T20
Value
at least 110 pounds
NCT03493919_inc_T21
Value
east 110 g), b
NCT03493919_inc_T22
Scope
at least 110 pounds (50 kg)
NCT03493919_inc_T23
Condition
obesity
NCT03493919_inc_T24
Measurement
BMI
NCT03493919_inc_T25
Negation
not to present
NCT03493919_inc_T26
Value
< 32kg/m2
NCT03493919_inc_T27
Person
Female
NCT03493919_inc_T28
Negation
non-
NCT03493919_inc_T29
Observation
childbearing potential
NCT03493919_inc_T30
Observation
pre-menarche
NCT03493919_inc_T31
Scope
BMI < 32kg/m2
NCT03493919_inc_T32
Temporal
current
NCT03493919_inc_T33
Condition
bilateral tubal ligation
NCT03493919_inc_T34
Condition
eral tubal liga sion, hys
NCT03493919_inc_T35
Scope
bilateral tubal ligation or occlusion
NCT03493919_inc_T36
Condition
hysterectomy
NCT03493919_inc_T37
Procedure
bilateral tubal ligation
NCT03493919_inc_T38
Procedure
eral tubal liga sion, hys
NCT03493919_inc_T39
Condition
bilateral ovariectomy
NCT03493919_inc_T40
Observation
post-menopause
NCT03493919_inc_T42
Procedure
bilateral ovariectomy
NCT03493919_inc_T41
Scope
pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause
NCT03493919_inc_T43
Scope
non-childbearing potential
NCT03493919_inc_T44
Scope
pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause
NCT03493919_inc_T45
Observation
contraception
NCT03493919_inc_T46
Qualifier
adequate
NCT03493919_inc_T47
Temporal
30 days prior to vaccination
NCT03493919_inc_T48
Reference_point
vaccination
NCT03493919_inc_T49
Value
negative
NCT03493919_inc_T50
Measurement
pregnancy test
NCT03493919_inc_T51
Temporal
on the day of vaccination
NCT03493919_inc_T52
Reference_point
vaccination
NCT03493919_inc_T53
Multiplier
continue
NCT03493919_inc_T54
Observation
adequate contraception
NCT03493919_inc_T55
Temporal
during the entire treatment period
NCT03493919_inc_T56
Temporal
for 1 month, after completion of the vaccination series
NCT03493919_inc_T57
Reference_point
completion of the vaccination series
NCT03493919_inc_T58
Scope
during the entire treatment period and for 1 month, after completion of the vaccination series